Intradermal delivery of recombinant vaccinia virus vector DIs induces gut-mucosal immunity

Scandinavian Journal of Immunology

Volumn 72, Issue 2, 2010, Pages 98-105

  Yoshino, N ^a,b   Kanekiyo, M ^b   Hagiwara, Y ^c   Okamura, T ^b   Someya, K ^b   Matsuo, K ^b   Ami, Y ^b   Sato, S ^a   Yamamoto, N ^b   Honda, M ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c KITASATO INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P27; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; HELPER CELL; HUMORAL IMMUNITY; INTESTINE MUCOSA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, VIRAL; DNA; FEMALE; GENE PRODUCTS, GAG; GENETIC VECTORS; IMMUNITY, MUCOSAL; IMMUNIZATION; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIFIC PATHOGEN-FREE ORGANISMS; STATISTICS, NONPARAMETRIC; VACCINIA VIRUS;

EID: 77954412196     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02416.x     Document Type: Article

References (53)

1. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006 12 : 930 939.
2. Ogra PL, Karzon DT, Righthand F et al. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 1968 279 : 893 900.
3. Ogra PL, Chiba Y, Beutner KR, Morag A. Vaccination by non-parenteral routes: characteristics of immune response. Dev Biol Stand 1976 33 : 19 26.
4. Kiyono H, Czerkinsky C. Consideration of mucosally induced tolerance in vaccine development. In : Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccine.
5. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996 93 : 11341 11348.
6. Tagaya I, Kitamura T, Sano Y. A new mutant of dermovaccinia virus. Nature 1961 192 : 381 382.
7. Kitamura T, Kitamura Y. Interference with the growth of vaccinia virus by an attenuated mutant virus. Jpn J Med Sci Biol 1963 16 : 343 357.
8. Kitamura T, Kitamura Y, Tagaya I. Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys. Nature 1967 215 : 1187 1188.
9. Ishii K, Ueda Y, Matsuo K et al. Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology 2002 302 : 433 444.
10. Ami Y, Izumi Y, Matsuo K et al. Priming-boosting vaccination with recombinant Mycobacterium bovis Bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 2005 79 : 12871 12879.
11. Someya K, Xin KQ, Matsuo K et al. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 2004 78 : 9842 9853.
12. Someya K, Ami Y, Nakasone T et al. Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol. J Immunol 2006 176 : 1784 1795.
13. Ishii K, Hasegawa H, Nagata N et al. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 2006 351 : 368 380.
14. Okamura T, Someya K, Matsuo K, Hasegawa A, Yamamoto N, Honda M. Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate. Microbiol Immunol 2006 50 : 989 1000.
15. McCluskie MJ, Davis HL. Novel strategies using DNA for the induction of mucosal immunity. Crit Rev Immunol 1999 19 : 303 329.
16. Stevceva L, Abimiku AG, Franchini G. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes Immun 2000 1 : 308 315.
17. Yoshino N, Kanekiyo M, Hagiwara Y et al. Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity. Scand J Immunol 2008 68 : 476 483.
18. Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003 289 : 3295 3299.
19. Greenberg RN, Kennedy JS, Clanton DJ et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005 365 : 398 409.
20. Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009 8 : 13 24.
21. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010 16 : 224 227.
22. Tagaya I, Amano H, Yuasa T. Improved plaque assay of a mutant of vaccinia virus, strain DIs, in chick embryo cell cultures. Jpn J Med Sci Biol 1974 27 : 245 247.
23. Morita M, Aoyama Y, Arita M et al. Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys. Arch Virol 1977 53 : 197 208.
24. Svennerholm AM, Holmgren J, Hanson LA, Lindblad BS, Quereshi F, Rahimtoola RJ. Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand J Immunol 1977 6 : 1345 1349.
25. Svennerholm AM, Hanson LA, Holmgren J, Lindblad BS, Nilsson B, Quereshi F. Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect Immun 1980 30 : 427 430.
26. Svennerholm AM, Hanson LA, Holmgren J et al. Antibody responses to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women. J Infect Dis 1981 143 : 707 711.
27. Wu HY, Russell MW. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 1993 61 : 314 322.
28. Tamura S, Miyata K, Matsuo K et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 1996 156 : 3892 3900.
29. Moldoveanu Z, Fujihashi K. Collection and processing of external secretions and tissues of mouse origin. In : Mestecky J, Lamm ME, McGhee JR, Bienenstock J, Mayer L, Strober W, eds. Mucosal Immunology, 3rd edn.
30. Yoshino N, Fujihashi K, Hagiwara Y et al. Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy. Vaccine 2009 27 : 4808 4817.
31. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985 161 : 526 546. (Pubitemid 15142803)
32. Unger RE, Marthas ML, Lackner AA et al. Detection of simian immunodeficiency virus DNA in macrophages from infected rhesus macaques. J Med Primatol 1992 21 : 74 81.
33. Pelizon AC, Martins DR, Zorzella-Pezavento SFG et al. Neonatal BCG immunization followed by DNAhsp65 boosters: highly immunogenic but not protective against tuberculosis - a paradoxical effect of the vector? Scand J Immunol 2010 71 : 63 9.
34. Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009 70 : 505 515.
35. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003 171 : 4969 4973.
36. Combadiere B, Boissonnas A, Carcelain G et al. Distinct time effects of vaccination on long-term proliferative and IFN-γ-producing T cell memory to smallpox in humans. J Exp Med 2004 199 : 1585 1593.
37. Romani N, Ratzinger G, Pfaller K et al. Migration of dendritic cells into lymphatics-the Langerhans cell example: routes, regulation, and relevance. Int Rev Cytol 2001 207 : 237 270.
38. Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008 372 : 260 272.
39. Vaerman JP, Langendries A, Giffroy D, Brandtzaeg P, Kobayashi K. Lack of SC/pIgR-mediated epithelial transport of a human polymeric IgA devoid of J chain: in vitro and in vivo studies. Immunology 1998 95 : 90 6.
40. Meckelein B, Externest D, Schmidt MA, Frey A. Contribution of serum immunoglobulin transudate to the antibody immune status of murine intestinal secretions: influence of different sampling procedures. Clin Diagn Lab Immunol 2003 10 : 831 834.
41. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007 25 : 5467 5484.
42. Quiding M, Nordström I, Kilander A et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest 1991 88 : 143 148.
43. Kozlowski PA, Cu-Uvin S, Neutra MR et al. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997 65 : 1387 1394.
44. Johansson EL, Bergquist C, Edebo A et al. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 2004 22 : 984 990.
45. Johansson EL, Wassén L, Holmgren J et al. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001 69 : 7481 7486.
46. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987 7 : 265 276.
47. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004 4 : 699 710.
48. Fujihashi K, Staats HF, Kozaki S, Pascual DW. Mucosal vaccine development for botulinum intoxication. Expert Rev Vaccines 2007 6 : 35 45.
49. Streilein JW. Skin-associated lymphoid tissue. Immunol Ser 1989 46 : 73 96.
50. Sontheimer RD. Perivascular dendritic macrophages as immunobiological constituents of the human dermal microvascular unit. J Invest Dermatol 1989 93 : 96S 101S.
51. Bos JD, Kapsenberg ML. The skin immune system: progress in cutaneous biology. Immunol Today 1993 14 : 75 8.
52. Nestle FO, Nickoloff BJ. A fresh morphological and functional look at dermal dendritic cells. J Cutan Pathol 1995 22 : 385 393.
53. + dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J Immunol 2008 180 : 4361 4365.